DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children

, MT Newswires -  4:21 AM ET 3/24/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

04:21 AM EDT, 03/24/2025 (MT Newswires) -- DBV Technologies ( DBVT ) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.

The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.

DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's "substantial doubt" about its ability to continue as a going concern.

The company said it is actively reviewing potential financing and strategic options with its financial advisers.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.